tw0122
6月前
Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateNovember 13 2025 - 4:01PM
https://twitter.com/sharehttp://www.facebook.com/sharer.php?s=100&p[url]=https%3A%2F%2Finvestorshub.advfn.com%2Fstock-market%2FNASDAQ%2Fvor-biopharma-VOR%2Fstock-news%2F97230791%2Fvor-bio-reports-third-quarter-2025-financial-resul
Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update.
“This has been a pivotal quarter for Vor Bio, as we continue to redefine success in autoimmune disease. Across multiple late-stage programs, telitacicept has now demonstrated consistent results on multiple efficacy endpoints, durable benefit, and a favorable safety profile, a rare combination in our field. We are especially pleased with the recent Phase 3 results in Sjögren’s disease in China where we saw sustained efficacy and a favorable safety profile through 48 weeks, supporting a potential best-in-disease profile,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of Vor Bio. “With proof of concept in five autoimmune indications and a global Phase 3 clinical trial underway in generalized myasthenia gravis, we are delivering on our vision to make telitacicept the most advanced BAFF/APRIL inhibitor globally and a true pipeline-in-a-product capable of transforming care for patients with serious autoimmune conditions.”Recent Corporate and Clinical Highlights
Telitacicept: A Potential Best-in-Class Dual BAFF/APRIL InhibitorGeneralized Myasthenia Gravis (gMG)
In October 2025, Vor Bio and its collaborator, RemeGen Co., Ltd., announced new 48-week open-label extension (OLE) data from the Phase 3 study in China evaluating telitacicept in generalized myasthenia gravis (gMG). Results were featured in an oral presentation at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting (AANEM) on October 29, 2025.Sjögren’s Disease (SD)
In October 2025, Vor Bio’s and its collaborator, RemeGen Co., Ltd, reported positive top-line Phase 3 results from the study of telitacicept in Sjögren’s disease in China. The results were also featured as a late-breaking poster presentation at the 2025 ACR Convergence Meeting on October 28, 2025.Systemic Lupus Erythematosus (SLE)
In October 2025, published results from the Phase 3 trial of telitacicept in patients with systemic lupus erythematosus (SLE) in China, reinforcing its potential as a disease-modifying therapy.IgA Nephropathy (IgAN)
At the American Society of Nephrology (ASN) Kidney Week 2025, Vor Bio and its collaborator, RemeGen Co., Ltd., reported positive Phase 3 results from the study evaluating telitacicept in adults with IgA nephropathy (IgAN) in China.Vor Bio significantly expanded its Leadership Team and Board in the third quarter to support late-stage development and commercial readiness:Leadership TeamBoard of DirectorsThird Quarter 2025 Financial ResultsAbout Telitacicept
Telitacicept is a novel, investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase 3 clinical trial in gMG is currently underway across the United States, Europe, South America, and Asia-Pacific to support potential approval in the United States, Europe, and Japan
INV4
11月前
$VOR 💹
July 3, 2025
After registering a 1.40% upside in the last session, Vor Biopharma Inc (VOR) has traded red over the past five days. The 5-day price performance for the stock is 161.54%, and 518.86% over 30 days. With these gigs, the year-to-date price performance is 45.00%. Short interest in Vor Biopharma Inc (NASDAQ:VOR) saw shorts transact 3.22 million shares and set a 0.79 days time to cover.
The extremes give us $3 and $3 for target low and target high price respectively. As such, VOR has been trading -106.9% off suggested target high and -106.9% from its likely low.
Vor Biopharma Inc (NASDAQ:VOR)’s Major holders
Vor Biopharma Inc insiders hold 31.89% of total outstanding shares, with institutional holders owning 48.46% of the shares at 71.15% float percentage. In total, 48.46% institutions holds shares in the company, led by RA CAPITAL MANAGEMENT, L.P.. As of 2024-06-30, the company held over 22.75 million shares (or 33.439% of shares), all amounting to roughly $22.75 million.
The next major institution holding the largest number of shares is FMR LLC with 7.08 million shares, or about 10.4009% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $7.08 million.
We also have VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund as the top two Mutual Funds with the largest holdings of the Vor Biopharma Inc (VOR) shares. Going by data provided on Mar 31, 2025 , VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund holds roughly 1.39 shares. This is just over 1.11% of the total shares, with a market valuation of $2.01 million. Data from the same date shows that the other fund manager holds a little less at 1.27, or 1.02% of the shares, all valued at about 1.85 million.
https://marketingsentinel.com/2025/07/03/vor-biopharma-inc-nasdaq-vor-has-fallen-40-69-from-its-highs-what-comes-next/
=======================
Insider Activity 12 Months
Number of Shares Bought 56,166,260
Number of Shares Sold 92,884
https://www.nasdaq.com/market-activity/stocks/vor/insider-activity
=======================
VOR Institutional Holdings
Institutional Ownership 49.06%
Total Shares Outstanding (millions) 125
Total Value of Holdings (millions) $89
https://www.nasdaq.com/market-activity/stocks/vor/institutional-holdings
$VOR